Abstract
Dabrafenib is a potent and selective inhibitor of BRAF-mutant kinase that is approved, as monotherapy or in combination with trametinib (mitogen-activ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
